Research and Markets (http://www.researchandmarkets.com/research/63kfhj/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Schizophrenia Overview
- Therapeutics Development
- Pipeline Products for Schizophrenia - Overview
- Pipeline Products for Schizophrenia - Comparative Analysis
- Schizophrenia - Therapeutics under Development by Companies
- Schizophrenia - Therapeutics under Investigation by Universities/Institutes
- Schizophrenia - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Schizophrenia - Products under Development by Companies
- Schizophrenia - Products under Investigation by Universities/Institutes
- Schizophrenia - Companies Involved in Therapeutics Development (Partial List)
- Acadia Pharmaceuticals Inc.
- Aequus Pharmaceuticals Inc.
- Aestus Therapeutics, Inc.
- AgeneBio Inc.
- Alkermes Plc
- Amgen Inc.
- Angita B.V.
- ANP Technologies, Inc.
- Astellas Pharma Inc.
- Athersys, Inc.
- BCWorld Pharm Co. Ltd.
- BioCrea GmbH
- Boehringer Ingelheim GmbH
- Braeburn Pharmaceuticals, Inc.
- Catalyst Biosciences, Inc.
- Critical Pharmaceuticals Limited
- Curemark, LLC
- Delpor, Inc.
- Dong Wha Pharma Co., Ltd.
- Echo Pharmaceuticals B.V.
- Egis Gyogyszergyar Nyrt
- Eli Lilly and Company
- Evotec AG
- F. Hoffmann-La Roche Ltd.
- FORUM Pharmaceuticals Inc.
- Galenea Corp.
- GeNeuro SA
- Genovate Biotechnology Co., LTD.
- Gilead Sciences, Inc.
- Glenmark Pharmaceuticals Ltd.
- GP Pharm, S.A.
For more information visit http://www.researchandmarkets.com/research/63kfhj/schizophrenia
View source version on businesswire.com: http://www.businesswire.com/news/home/20160205005779/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central
Nervous System, Mental
Disorders